Second-generation biopharmaceuticals

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 58, Issue 2, 2004, Pages 185-196

  Walsh, Gary ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

Biopharmaceutical; PEGylation; Protein engineering

Indexed keywords

ABCIXIMAB; AGALSIDASE ALFA; AGALSIDASE BETA; ALEFACEPT; ALEMTUZUMAB; ALFATRONOL; ALTEPLASE; ARCITUMOMAB TC 99M; BASILIXIMAB; BAYOVAC CSF E2; BECAPLERMIN; BETA1A INTERFERON; CAPROMAB PENDETIDE IN 111; CONSENSUS INTERFERON; DACLIZUMAB; DENILEUKIN DIFTITOX; DROTRECOGIN; ETANERCEPT; EURIFEL FELV; EURIFEL RCPFEVL; FEVAXYN PENTOFEL; GALLIVAC HVT IBD; GAMMA1B INTERFERON; GEMTUZUMAB OZOGAMICIN; GLYCOSYLATED PROTEIN; HUMAN GROWTH HORMONE; HUMAN INSULIN; IBRAXION; IBRITUMOMAB TIUXETAN; IMIGLUCERASE; INDIMACIS; INFLIXIMAB; INFUSE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; MACROGOL; MYOSIN ANTIBODY IN 111; NEOCOLIPOR; NEUTRAL INSULIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OKT 3; OMALIZUMAB; ONCOSCINT; OSTEOGENIC PROTEIN 1; PALIVIZUMAB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; PORCILIS AR T DF; PORCILIS PESTI; PORCILIS PORCOLI; PROTEQFLU; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RECOMBINANT GLUCAGON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN INSULIN; RECOMBINANT LUTEINIZING HORMONE; RECOMBINANT THYROTROPIN; RETEPLASE; RITUXIMAB; SOMATREM; SULESOMAB TC 99M; TASONERMIN; TECNEMAB KI; TENECTEPLASE; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERLUMA; VIBRAGEN OMEGA; VIRTRON;

AMINO ACID SEQUENCE; COVALENT BOND; DRUG APPROVAL; DRUG INDUSTRY; HUMAN; IMMUNOLOGY; NONHUMAN; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; BIOLOGICAL PRODUCTS; COMBINATORIAL CHEMISTRY TECHNIQUES; HUMANS; PROTEIN CONFORMATION; PROTEIN ENGINEERING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3843142857     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2004.03.012     Document Type: Review

References (74)

1. Jackson D.A., Symons R.H., Berg P. Biochemical method for inserting new genetic information into DNA of simian virus 40: circular SV 40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc. Natl Acad. Sci. USA. 69:1972;2904-2909
2. Lobban P.E., Kaiser A.D. Enzymatic end to end joining of DNA molecules. J. Mol. Biol. 78:1973;453-471
3. Kohler G., Milstein C. Continuous culture of fused cells secreting antibody of pre-defined specificity. Nature. 256:1975;495-497
4. Walsh G. Biopharmaceuticals and biotechnology medicines: an issue of nomenclature. Eur. J. Pharm. Sci. 15:2002;135-138
5. Johnson I. Human insulin from recombinant DNA technology. Science. 219:1983;632-637
6. Walsh G. Biopharmaceutical benchmarks - 2003. Nat. Biotechnol. 21:(8):2003;865-870
7. Robinson K. An industry comes of age. Biopharm. Int. 15:(11):2002;20-24
8. Carey P. Protein Engineering and Design. 1996;Academic Press, London
9. Brannigan J.A., Wilkinson A.J. Protein engineering 20 years on. Nat. Rev. Mol. Cell Biol. 3:(12):2002;964-970
10. Van Ee J. Enzymes in Detergency. 1997;Marcel Dekker, New York, USA
11. Bristol A. Recombinant DNA derived insulin analogues as potentially useful therapeutic agents. Trends Biotechnol. 11:1993;301-305
12. Vajo Z., Duckworth W. Genetically engineered insulin analogues: diabetes in the new millennium. Pharmacol. Rev. 52:(1):2000;1-9
13. Chance R.E., Franks B.H., Radziuk J.M., Di Marchi R. Discovery and development of insulin lispro. Drugs Today. 34:(Suppl. C):1998;1-9
14. Breams D.N., Alter L.A., Beckage M.J. Altering the association properties of insulin by amino acid replacement. Protein Eng. 5:(6):1992;527-533
15. Cohick W., Clemmons D. The insulin-like growth factors. Annu. Rev. Physiol. 55:1993;131-153
16. Long H.B. Human insulin analogues with rapid onset and short duration of action. Smith J.A., Rivier J.E. Peptides. Chemistry and biology. Proceedings of the Twelfth American Peptide Symposium. 1992;88-90 ESCOM, Leiden
17. Franks B.H. Manipulation of the position of proline in the B chain produces monomeric insulins. Diabetes. 40:(Suppl. 1):1991;423A
18. R.E. Chance, Insulin analogues modified at position 29 of the B chain, US Patent 5,514,646, 1996.
19. Slieker L.J., Brooke G.S., Di Marchi R.D. Modification in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia. 40:(Suppl. 2):1997;S54-S61
20. Shaw W.N., Su K. Biological aspects of a new human insulin analog: [Lys(B28), Pro(B29)]-human insulin. Diabetes. 40:(Suppl. 1):1991;464A
21. Galloway J.A. Human insulin and its modifications. Reidenberg M. The Clinical Pharmacology of Biotechnology Products. 1991;23-34 Elsevier, Amsterdam
22. Su K.S. Using dog model for comparing time action of insulins after subcutaneous (s.c.) injection: prediction of rapid onset of a new insulin analogue [Lys (B28), Pro (B29)]-human insulin (KP). Pharm. Res. 11:(10):1994;S357
23. B29-insulin: dissociation of a protein-ligand complex. Protein Sci. 5:(12):1996;2521-2531
24. B29 - human insulin - assessed in a conscious pig model. Diabetes. 46:1997;548-556
25. Chance R.E., Glazer N.B., Wishner K.L. Insulin Lispro (Humalog). Walsh G., Murphy B. Biopharmaceuticals, An Industrial Perspective. 1999;149-171 Kluwer Academic Publications, Dordecht, The Netherlands
26. Howey D.C., Bowser R.R., Brunelle R.L. [Lys (B28), Pro (B29)]-human insulin: effect of injection time on postprandial glycemia. Clin. Pharmacol. Ther. 58:1995;459-469
27. Heinemann L., Woodworth J. Pharmacokinetics and glucodynamics of insulin lispro. Drugs Today. 32:(Suppl. C):1998;23-36
28. Heinemann L., Heise T., Wahl L.C. Prandial glycaemia after a carbohydrate-rich meal in type 1 diabetic patients: using the rapid acting insulin analogue [Lys (B28), Pro (B29)] human insulin. Diabet. Med. 13:1996;625-629
29. B29-human insulin (insulin lispro): solution properties of a rapid-acting insulin. Diabetologia. 38:(Suppl. 1):1995;A189
30. Chapman T.M., Noble S., Goa K.L. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs. 62:2002;1945-1981
31. Setter S.M., Corbett C.F., Campbell R.K. Insulin aspart: a new rapid acting insulin analog. Ann. Pharmacother. 34:2000;1423-1431
32. Owens D.R., Griffiths S. Insulin glargine (Lantus). Int. J. Clin. Pract. 56:2002;460-466
33. McKeage K., Goa K.L. Insulin glargine: a review of its therapeutic use as a long acting agent for the management of type 1 and 2 diabetes mellitus. Drugs. 61:2001;1599-1624
34. Gillis J., Wagstaff A.J., Goa K.L. Alteplase: a reappraisal of its pharmacological properties and therapeutic uses in acute myocardial infarction. Drugs. 50:1995;102-136
35. Verstacte M. Third generation thrombolytic agents. Am. J. Med. 109:2000;52-58
36. Waller M., Kohnert U. Reteplase, a recombinant plasminogen activator. Walsh G., Murphy B. Biopharmaceuticals, An Industrial Perspective. 1999;185-216 Kluwer Academic Publisher, Dordecht, The Netherlands
37. Wooster M.B., Luzier A.B. Reteplase: a new thrombolytic for the treatment of acute myocardial infarction. Ann. Pharmacother. 33:1999;318-324
38. Noble S., McTavish D. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs. 52:1996;589-605
39. Davydov L., Cheng J.W. Tenecteplase: a review. Clin. Ther. 23:2001;982-997
40. Berger M., Shankar V., Vafai A. Therapeutic applications of monoclonal antibodies. Am. J. Med. Sci. 324:2002;14-30
41. Breedveld F. Therapeutic monoclonal antibodies. Lancet. 355:2000;735-740
42. Walsh G. Biopharmaceuticals: Biochemistry and Biotechnology. second ed.:2003;Wiley, Chichester, UK. pp. 403-461
43. Harris W. Antibody Therapeutics. 1997;CRC Press, Florida, USA
44. Kontermann R. Antibody Engineering. 2001;Springer, Berlin
45. Nihira S. Experiences in drug discovery and development of anti-erbB2 (HER 2) monoclonal antibody; Herceptin. J. Pharmacol. Sci. 91:2003;63P
46. Hendler G. Her-2: the making of herceptin, a revolutionary treatment for breast cancer. Libr. J. 123:(15):1998;102
47. Anon. Palivizumab (Synagis) - monoclonal antibody for disease prevention. Am. J. Nurs. 99:(1):1999;52
48. Lacha J., Simova M., Noskova L., Telpan V., Vitko S. Zenapax versus OKT-3 prophylaxis in immunologically high risk kidney transplant recipients. Transplant. Proc. 33:(3):2001;2273-2274
49. Emre S., Vanin A., Crevantes E., Heidt D., Fishbein T., Sheiner P., Schwartz M., Miller C. Use of daclizumab (Zenapax) as initial immunosuppression in liver transplant recepients with kidney failure. Transplantation. 67:(9):1999;231
50. Olsen E., Duvic M., Frankel A. Pivitol phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T cell lymphoma. J. Clin. Oncol. 19:2001;376-388
51. Foss F.M. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Ann. N.Y. Acad. Sci. 941:2001;166-176
52. Duvic M., Kuzel T., Olsen E.A. Quality of life improvements in cutaneous T cell lymphoma patients treated with denileukin diftitox (ontak). Clin. Lymphoma. 2:2002;222-228
53. Moreland L.W. Soluble tumor necrosis factor receptor (p75) fusion protein (Enbrel) as a therapy for rheumatoid arthritis. Rheum. Dis. Clin. North Am. 24:1998;579-591
54. Alldred A. Etanercept in rheumatoid arthritis. Expert Opin. Pharmacother. 2:2001;1137-1148
55. Ellis C., Krueger G.C. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345:2001;248-255
56. Frampton J.E., Wagstaff A.J. Alfacept. Am. J. Clin. Dermatol. 4:2003;277-286
57. Krueger G.G., Callis K.P. Development and use of alefacept to treat psoriasis. J. Am. Acad. Dermatol. 49:2003;587-597
58. Jiang Z.Y., Xu S.W., Wang Y.Q. Chemistry for Pegylation of protein and peptide molecules. Chin. J. Org. Chem. 23:2003;1340-1347
59. Greenwald R.B., Choe Y.H., McGuire J., Conover C.D. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55:2003;217-250
60. Harris J.M., Martin N.E., Modi M. Pegylation - a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40:2001;539-551
61. Wang Y., Youngster S., Grace M. Structural and biological characterization of PEGylated recombinant interferon α2B and its therapeutic implications. Adv. Drug Deliv. Rev. 54:2002;547-570
62. Patel K., Hutchison J. PEGylated interferon α-2b: a new approach to improving response in hepatitis C patients. Expert Opin. Pharmacother. 2:2001;1307-1315
63. Hadziyannis S.J., Papatheodoridis G.V. Peginterferon-alpha (2a) (40 kDa) for chronic hepatitis C. Expert Opin. Pharmacother. 4:2003;541-551
64. Parkinson C., Trainer P.J. The place of Pegvisomant in the management of acromegaly. Endocrinologist. 13:2003;408-416
65. Anon. Pegvisomant-Trovert-Somavert - treatment of acromegaly. Drug Future. 26:2001;911-913
66. Clark R., Olson K., Fiuh G. Long acting growth hormones produced by conjugation with polyethylene glycol. J. Biol. Chem. 271:1996;21969-21977
67. Hoppe H. Cerezyme - recombinant protein treatment for Gaucher's disease. J. Biotechnol. 76:2000;259-261
68. Niederau C. First long term results of Imiglucerase therapy of type 1 Gaucher's disease. Eur. J. Med. Res. 3:1998;25-30
69. Glaspy J.A., Jadeja J.S., Justice G. Darbepoietin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br. J. Cancer. 87:2002;268-276
70. Joy M.S. Darbepoetin alfa: a new erythropoiesis-stimulating protein. Ann. Pharmacother. 36:2002;1183-1192
71. Berg C., Nassar R., Pang K. The evolution of biotech. Nat. Rev. Drug. Discov. 1:2002;845-846
72. Glennie M.J., Johnson P.W.M. Clinical trials of antibody therapy. Immunol. Today. 21:2000;403-410
73. Brekki O.H., Sandlie I. Therapeutic antibodies for human disease at the dawn of the twenty-first century. Nat. Rev. Drug. Discov. 2:2003;52-62
74. Walsh G. Biopharmaceuticals: first versus second generation. New Drugs. 2:2002;26-37